Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.49 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.49 |
| ▸ | BRD2 | P25440 | 3/20 | 0.49 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL33532847 | 0.95 | BRD4 (0.49) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33532986 | 0.90 | BRD4 (0.50) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33533424 | 0.86 | BRD4 (0.49) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33532825 | 0.84 | BRD9 (0.48) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL23798993 | 0.84 | BRD9 (0.57) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL23783038 | 0.83 | BRD4 (0.53) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL30297131 | 0.83 | BRD4 (0.51) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33533254 | 0.82 | BRD9 (0.49) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL25091505 | 0.82 | BRD9 (0.55) | BRD4BRD9BRD2BRD7CYP3A4 | |
| SCHEMBL33533083 | 0.82 | BRD9 (0.51) | BRD4BRD9BRD2BRD7CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119823124-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| CN-115279370-B | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-01-10 | — | — | CN | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| WO-2021178920-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD2 6/4885 |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD2 6/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD2 6/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD2 6/4885 |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD2 6/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | BRD4 30/4885BRD9 1/4885BRD2 6/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD4 17/4885BRD9 1/4885BRD2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.